Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence
worldwide, ranking among the top five malignant tumors worldwide in terms of incidence …

Immunotherapy (IO) agents have led to significant improvements in patient outcomes across
many tumor types. There have been great efforts to introduce immune checkpoint inhibitors …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the
potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the …

Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …

Background Targeting the DNA damage repair (DDR) pathways is an attractive strategy for
boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia …

In this multi-center phase II trial, we evaluated the efficacy and safety of a quadruplet
regimen (pembrolizumab, trastuzumab, and doublet chemotherapy) as first-line therapy for …

Gastric adenocarcinoma, even when diagnosed at an early (localized) disease stage, poses
a major health-care burden with cure rates that remain unsatisfactorily low, particularly in …